Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Completed
GlaxoSmithKline
Phase 3
2016-09-27
The purpose of this multi-center event-driven study in non-dialysis (ND) participants with
anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of
daprodustat compared to darbepoetin alfa.
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
Completed
GlaxoSmithKline
Phase 3
2016-09-28
The purpose of this multi-center event-driven study in participants with anemia associated
with chronic kidney disease (CKD) to evaluate the safety and efficacy of daprodustat.
A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)
Completed
GlaxoSmithKline
Phase 3
2016-11-21
Daprodustat is a drug that is currently being developed as a treatment for renal anemia .
This study is to evaluate the efficacy and safety of daprodustat following a switch from
erythropoiesis-stimulating agent (ESA) in Japanese HD subjects with renal anemia who are
currently treated with ESA. The primary objective is to demonstrate non-inferiority of
daprodustat to darbepoetin alfa. This study is a 52-week, Phase III, double-blind,
active-controlled, parallel-group, multi-center study. The total duration of the study will
be approximately 58 weeks including screening and follow-up.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
